These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10960842)

  • 1. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
    del Vecchio MT; Tripodi SA; Arcuri F; Pergola L; Hako L; Vatti R; Cintorino M
    Prostate; 2000 Sep; 45(1):51-7. PubMed ID: 10960842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
    Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
    Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
    Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
    Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
    Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
    Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
    J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.
    Wheeler TM
    Eur Urol; 1996; 30(2):261-4. PubMed ID: 8875209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
    Tran TA; Jennings TA; Ross JS; Nazeer T
    Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
    Meyer-Siegler KL; Iczkowski KA; Vera PL
    BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 12. Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.
    Ambrosio MR; Rocca BJ; Barone A; Ginori A; Crivelli F; Pirtoli L; Del Vecchio MT
    Anticancer Res; 2015 Oct; 35(10):5595-600. PubMed ID: 26408731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes.
    Rocca BJ; Ginori A; Barone A; Calandra C; Crivelli F; De Falco G; Gazaneo S; Tripodi S; Cevenini G; del Vecchio MT; Ambrosio MR; Tosi P
    Biomed Res Int; 2015; 2015():985950. PubMed ID: 25667934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
    BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
    Helpap B
    Virchows Arch; 2006 Apr; 448(4):480-4. PubMed ID: 16506014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.
    Kamimura A; Kamachi M; Nishihira J; Ogura S; Isobe H; Dosaka-Akita H; Ogata A; Shindoh M; Ohbuchi T; Kawakami Y
    Cancer; 2000 Jul; 89(2):334-41. PubMed ID: 10918163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.